MedTrace Logo

A Phase 3 Clinical Study of KHK 4827

NCT02052609 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2023-08-25

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

Conditions

  • Psoriasis Vulgaris
  • Psoriatic Arthritis
  • Pustular; Psoriasis, Palmaris Et Plantaris
  • Psoriatic Erythroderma

Interventions

DRUG

KHK4827 140mg SC

Experimental1:KHK4827 140mg subcutaneous injection

DRUG

KHK4827 210mg SC

Experimental2:KHK4827 210mg subcutaneous injection

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-01-28
Completion
2016-07-04

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052609 on ClinicalTrials.gov